Download or read book Anti Angiogenic Therapy in Ophthalmology written by Andreas Stahl and published by Springer. This book was released on 2016-05-13 with total page 198 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a concise overview over the pathology of retinal angiogenic diseases and explains why anti-angiogenic therapy is effective in so many patients. The reader is guided through the various clinical indications for anti-angiogenic therapy and made aware of its merits as well as current challenges and limitations. It is explained how, since its introduction for the treatment of exudative age-related macular degeneration in 2006, anti-angiogenic therapy has revolutionized the way in which we treat a range of ocular diseases. All of the authors are established experts in their respective fields who share their extensive knowledge and clinical experience with the reader. This book is both a valuable introduction to anti-angiogenic therapy in ophthalmology and a day-to-day companion for all ophthalmologists seeing patients with some of the most prevalent retinal diseases.
Download or read book Therapy for Ocular Angiogenesis written by Arup Das and published by Lippincott Williams & Wilkins. This book was released on 2012-03-28 with total page 896 pages. Available in PDF, EPUB and Kindle. Book excerpt: Ocular angiogenesis, or the abnormal growth of blood vessels in the eye, is the cause of major neovascular eye diseases. With the new era of anti-angiogenic therapies, ophthalmologists have started treating many ocular diseases including macular degeneration, diabetic retinopathy, and retinal vascular occlusion using anti-angiogenic drugs. This book covers the basic pathophysiology of ocular angiogenesis and strategies for inhibition. The authors discuss the "Principles" of anti-angiogenic therapy, pre-clinical studies, future drugs on the horizon, drug delivery, and the "Practice" of the therapy in many ocular diseases. The book also includes chapters on diabetic macular edema, and various therapeutic options for this condition. A companion website includes the fully searchable text and an image bank.
Download or read book Ocular Angiogenesis written by Joyce Tombran-Tink and published by Springer Science & Business Media. This book was released on 2007-11-06 with total page 409 pages. Available in PDF, EPUB and Kindle. Book excerpt: Leading academic and pharmaceutical researchers and clinicians from many disciplines synthesize and summarize current clinical and basic knowledge concerning abnormal growth of blood vessels in the eye, the cause of major neovascular eye diseases. The authors also identify and assess the most promising approaches with potential for commercial exploitation and discuss the challenges encountered in developing therapeutics for ocular neovascular diseases. Highlights include illuminating chapters on gene therapy and novel drug delivery systems and excellent summaries of the newest therapeutic approaches.
Download or read book Anti VEGF written by M. Battaglia Parodi and published by Karger Medical and Scientific Publishers. This book was released on 2010-08-13 with total page 155 pages. Available in PDF, EPUB and Kindle. Book excerpt: The development of therapy with anti-angiogenics or vascular endothelial growth factor inhibitors (anti-VEGF) has marked the beginning of a new era in neovascularization and macular edema treatment. Its main goals are the inhibition of growth and development of new vessels along with the reduction of vascular permeability. The advantages over conventional laser photocoagulation are evident as laser treatment always leaves scars and causes a retinal sensitivity deterioration.Starting with an outline of treatment principles, this volume covers all aspects of anti-VEGF therapy for ophthalmological disorders. In particular, specific chapters are dedicated to age-related macular degeneration, degenerative myopia, angioid streaks, inflammatory diseases, hereditary dystrophies, retinal vein occlusion, diabetic retinopathy, ocular tumors, as well as anterior segment neovascularization.The book gives an update on the application of anti-VEGF in ocular diseases to general ophthalmologists as well as retina specialists.
Download or read book Retinal and Choroidal Angiogenesis written by John Penn and published by Springer Science & Business Media. This book was released on 2008-01-19 with total page 567 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book provides a comprehensive, in-depth review of our current understanding of the growth of blood vessels within the eye. Novel therapeutic strategies for the treatment of ocular angiogenesis are discussed, as are the unique challenges presented by delivery of drugs to the eye. The book emphasizes basic principles rather than specific experimental results, although recently acquired data is frequently cited to illustrate points of broader theoretical significance.
Download or read book Anti VEGF Use in Ophthalmology written by Jay Duker and published by CRC Press. This book was released on 2024-06-01 with total page 294 pages. Available in PDF, EPUB and Kindle. Book excerpt: The introduction of anti-vascular endothelial growth factor (VEGF) agents has revolutionized therapy for a host of ocular diseases associated with leakage from normal blood vessels and pathologic blood vessel growth. Anti-VEGF Use in Ophthalmology is an all-inclusive reference designed to provide detailed, up-to-date, and clinically relevant information on the current use of anti-VEGF agents in the treatment of all ocular conditions. Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use. The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents. Some of the topics covered in Anti-VEGF Use in Ophthalmology: Neovascular Age-Related Macular Degeneration Proliferative Diabetic Retinopathy Retinal Vein Occlusion Uveitis Neovascular Glaucoma Macular Edema Retinopathy of Prematurity Corneal Disease Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease.
Download or read book Anti VEGF Use in Ophthalmology written by Jay S. Duker and published by CRC Press. This book was released on 2017 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: The introduction of anti-vascular endothelial growth factor (VEGF) agents has revolutionized therapy for a host of ocular diseases associated with leakage from normal blood vessels and pathologic blood vessel growth. Anti-VEGF Use in Ophthalmology is an all-inclusive reference designed to provide detailed, up-to-date, and clinically relevant information on the current use of anti-VEGF agents in the treatment of all ocular conditions. Drs. Jay S. Duker and Michelle C. Liang have assembled a prestigious group of contributors who pool their collective expertise in this comprehensive book. Anti-VEGF Use in Ophthalmology is split into two sections with the first providing the history of VEGF and an overview of anti-VEGF agents and different routes of drug delivery, as it is important for eye care providers to be familiar with up-to-date aspects of the medications and indications for use. The second section details the clinical uses of anti-VEGF agents in numerous ocular diseases, from the anterior segment including cornea and glaucoma to uveitis and various retinal and choroidal diseases. Each chapter in this section summarizes the disease process and utilizes high-quality ocular imaging to demonstrate the therapeutic use of the anti-VEGF agents. Some of the topics covered in Anti-VEGF Use in Ophthalmology Neovascular Age-Related Macular Degeneration Proliferative Diabetic Retinopathy Retinal Vein Occlusion Uveitis Neovascular Glaucoma Macular Edema Retinopathy of Prematurity Corneal Disease Anti-VEGF Use in Ophthalmology combines the theory and applications of anti-VEGF agents, making it not only a great learning tool for beginners but also a useful reference tool for a wide range of eye care professionals including optometrists, residents, comprehensive ophthalmologists, as well as specialists in anterior segment, pediatrics, and vitreoretinal disease.
Download or read book Inhibitors of corneal inflammation and angiogenesis written by Pierfrancesco Mirabelli and published by Linköping University Electronic Press. This book was released on 2019-04-30 with total page 91 pages. Available in PDF, EPUB and Kindle. Book excerpt: Pathologic angiogenesis is involved in cancer and several blinding conditions such as wet age-related macular degeneration, proliferative retinopathies and corneal neovascularization. In these dieseases, the angiogenic triggers are hypoxia and inflammation, and both involve the main angiogenic mediator, which is Vascular Endothelial Growth Factor (VEGF). Among available treatments, anti-VEGF often shows limited or temporary efficacy, while steroids are potentially responsible for many side-effects. This thesis presents a series of linked studies aimed at elucidating the early pathologic changes leading to inflammation and corneal neovascularization, and how various treatments affect this process. In this thesis, anti-inflammatory and anti-angiogenic treatments are applied in corneal neovascularization models, to identify VEGF-independent pathways and other novel factors as future therapy targets, as well as to investigate the endogenous modulation of angiogenesis. A model of experimental neovascularization in the rat cornea was used as main model, where the neovascular response is triggered by a surgical suture placed into the cornea. Investigational treatments (anti-Vegf, dexamethasone, IMD0354, Gap27, or control substances) were then given topically, with the exception of IMD0354, which was given systemically. The effects in the cornea were studied in vivo with slit lamp photography to assess and quantify macroscopic vessel growth and using in vivo confocal microscopy (IVCM) to study cell infiltration and limbal vessel dilation and detect microscopic vessel sprouts; these examinations were performed longitudinally. Genomic analysis with RNA microarray, selected gene expression with q-RT-PCR, and selected protein expression in tissue (immunohistochemistry, immunofluorescence, Western blot) were performed at different time-points. Moreover, other experiments on cell cultures (HUVEC and HCEC), organ cultures (human corneas), ex vivo models (aortic rings) and in vivo studies (zebrafish vasculogenesis) were performed. Dexamethasone suppressed limbal vasodilation and corneal neovascularization more than anti-Vegf, despite no difference in inflammatory cell infiltration into the cornea. Five-hundred eleven fewer genes were differentially expressed in dexamethasone-treated corneas relative to naïve corneas, compared to anti-Vegf. Among them, several major pro-angiogenic and pro-inflammatory factors and chemokines were suppressed only by dexamethasone and represent novel candidate factors to target in order to improve anti-VEGF treatment. On the other hand, selective inhibition of a single inflammatory pathway (NF-?B), despite showing similar early effects as dexamethasone in suppressing tissue inflammation, was not effective enough to suppress new vessel growth. The same factors suppressed by dexamethasone are also inhibited in endogenous modulation of angiogenesis. Surprisingly, dexamethasone activated several complement factors, which could possibly be beneficial in the anti-angiogenic response. In a different therapeutic approach, promoting cell migration to accelerate epithelial wound closure similarly was not sufficient to avoid inflammation and angiogenesis in the cornea. In conclusion, new and more effective treatments are needed for corneal inflammation and neovascularization with fewer side-effects. In this thesis, several novel factors and mechanisms related to inflammation are identified, factors that are not addressed by anti-Vegf therapy, and therefore represent interesting objects for further study, as they have the potential to be targets for adjuvant therapy. Specific anti-inflammatory treatment as well as therapeutic activation of endogenous regulatory pathways, and potentially complement modulation, might represent new strategies to improve anti-angiogenic therapy, but when used alone they do not seem to avoid corneal neovascularization.
Download or read book Regulation of inflammation and angiogenesis in the cornea written by Anthony Mukwaya and published by Linköping University Electronic Press. This book was released on 2018-05-21 with total page 76 pages. Available in PDF, EPUB and Kindle. Book excerpt: Inflammation and angiogenesis, the growth of new blood vessels from pre-existing ones, are involved in tumor growth, ocular diseases and wound healing. In ocular angiogenesis, new pathological vessels grow into a specific eye tissue, leak fluid, and disrupt vision. The development of safe and effective therapies for ocular angiogenesis is of great importance for preventing blindness, given that current treatments have limited efficacy or are associated with undesirable side effects. The search for alternative treatment targets requires a deeper understanding of inflammation and how it can lead to angiogenesis in the eye in pathologic situations. This thesis provides new insights into the regulation of inflammation and angiogenesis, particularly at the gene expression and phenotypic levels, in different situations characterized by angiogenesis of the cornea, often called corneal neovascularization. For instance, specific genes and pathways are either endogenously activated or suppressed during active inflammation, wound healing, and during resolution of inflammation and angiogenesis, serving as potential targets to modulate the inflammatory and angiogenic response. In addition, as part of the healing response to restore corneal transparency, inflammation and angiogenesis subside with time in the cornea. In this context, LXR/RXR signaling was found to be activated in a time-dependent manner, to potentially regulate resolution of inflammation and angiogenesis. During regression of new angiogenic capillaries, ghost vessels and empty basement membrane sleeves are formed, which can persist in the cornea for a long time. Here, ghost vessels were found to facilitate subsequent revascularization of the cornea, while empty basement membrane sleeves did not revascularize. The revascularization response observed here was characterised by vasodilation, increased inflammatory cell infiltration and by sprouting at the front of the reperfused vessels. Importantly, reactive oxygen species and nitrous oxide signaling among other pro-inflammatory pathways were activated, and at the same time anti-inflammatory LXR/RXR signaling was inhibited. The interplay between activation and inhibition of these pathways highlights potential mechanisms that regulate corneal revascularization. When treating corneal neovascularization clinically, corticosteroids are in widespread use due to their effectiveness. To minimize the many undesirable side effects associated with corticosteroid use, however, identifying new and more selective agents is of great importance. Here, it was observed that corticosteroids not only suppressed pro-inflammatory chemokines and cytokines, but also activated the classical complement pathway. Classical complement may represent a candidate for further selective therapeutic manipulation to investigate its effect on treatment of corneal neovascularization. In summary, this thesis identifies genes, pathways, and phenotypic responses involved in sprouting and remodeling of corneal capillaries, highlights novel pathways and factors that may regulate inflammation and angiogenesis in the cornea, and provides insights into regulation of capillary regression and reactivation. Further investigation of these regulatory mechanisms may offer alternative and effective treatment targets for the treatment of corneal inflammation and angiogenesis.
Download or read book Therapeutic Antibodies written by Yuti Chernajovsky and published by Springer. This book was released on 2007-11-22 with total page 380 pages. Available in PDF, EPUB and Kindle. Book excerpt: This essential work, edited by two researchers at London’s famous Queen Mary’s medical school targets one of the most important areas in medical development today. These days, antibody therapeutics are the treatment of choice for several autoimmune and oncological conditions. They are, indeed, becoming the molecules of choice for further combination therapies and cell engineering. In this timely work, a slew of expert in the field of drug development summarize all the current developments and clinical successes.
Download or read book Anti VEGF Monotherapy as Treatment of Wet Age Related Macular Degeneration written by Dharti Joshi and published by . This book was released on 2014 with total page 40 pages. Available in PDF, EPUB and Kindle. Book excerpt: Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in people over the age of 50 in the developed world. Although majority of individual's suffering from the condition have the dry form of the condition, it is the wet AMD that results in detrimental vision loss. This past decade has seen a great advancement in treatment of wet AMD through use of anti-angiogenic therapy in the form of anti-vascular endothelial growth factors (anti-VEGF) agents. In addition to halting the damage caused by angiogenic factors, anti-VEGF therapy also aims at preventing vision loss thus, making it a primary choice of physicians in treatment of wet AMD. This review aims at presenting a comprehensive summery of all of the currently available anti-VEGF drugs including their safety, efficacy and appropriate modality of treatment.
Download or read book The Role of COX 2 in Pathological Ocular Angiogenesis written by Susan Elizabeth Yanni and published by . This book was released on 2010 with total page 135 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Angiogenesis written by Michael E. Maragoudakis and published by Springer Science & Business Media. This book was released on 2012-12-06 with total page 372 pages. Available in PDF, EPUB and Kindle. Book excerpt: Proceedings of the 5th Biannual International Meeting on Angiogenesis: From the Molecular to Integrative Pharmacology, held July 1-7, 1999, in Crete, Greece. Angiogenesis, as a vastly complex biological process, has challenged researchers from all basic scientific disciplines, including pharmacology, biochemistry, physiology, embryology and anatomy. The significance of this phenomenon for the study of disease states has also interested clinicians from a number of specialist fields. This multidisciplinary work reflects the growth of awareness of concepts such as angiogenesis based therapy, the enormous therapeutic and commercial potential of which has attracted major research and investment in recent years. This volume, which aims to bridge the gap between basic and clinical methodology and understanding, presents the most up-to-date developments in this field.
Download or read book Human Embryonic Stem Cells written by Jon Odorico and published by Garland Science. This book was released on 2004-02-01 with total page 391 pages. Available in PDF, EPUB and Kindle. Book excerpt: Since the first successful isolation and cultivation of human embryonic stem cells at the University of Wisconsin, Madison in 1998, there has been high levels of both interest and controversy in this area of research. This book provides a concise overview of an exciting field, covering the characteristics of both human embryonic stem cells and pluripotent stem cells from other human cell lineages. The following chapters describe state-of-the-art differentiation and characterization of specific ectoderm, mesoderm and endoderm-derived lineages from human embryonic stem cells, emphasizing how these can be used to study human developmental mechanisms. A further chapter discusses genetic manipulation of human ES cells. The concluding section covers therapeutic applications of human ES cells, as well as addressing the ethical and legal issues that this research have raised.
Download or read book Chemoprevention of Cancer written by Daniel W. Nixon and published by CRC Press. This book was released on 1994-11-08 with total page 160 pages. Available in PDF, EPUB and Kindle. Book excerpt: Chemoprevention of Cancer guides you through the exciting new field of cancer chemoprevention. It covers epidemiology, known chemopreventive compounds, development of new chemopreventive agents, specific examples of preventive agents and their mechanisms of action, and current prevention clinical trials.
Download or read book Vascular Development written by Derek J. Chadwick and published by John Wiley & Sons. This book was released on 2007-08-20 with total page 260 pages. Available in PDF, EPUB and Kindle. Book excerpt: The formation of blood vessels is an essential aspect of embryogenesis in vertebrates. It is a central feature of numerous post-embryonic processes, including tissue and organ growth and regeneration. It is also part of the pathology of tumour formation and certain inflammatory conditions. In recent years, comprehension of the molecular genetics of blood vessel formation has progressed enormously and studies in vertebrate model systems, especially the mouse and the zebrafish, have identified a common set of molecules and processes that are conserved throughout vertebrate embryogenesis while, in addition, highlighting aspects that may differ between different animal groups. The discovery in the past decade of the crucial role of new blood vessel formation for the development of cancers has generated great interest in angiogenesis (the formation of new blood vessels from pre-existing ones), with its major implications for potential cancer-control strategies. In addition, there are numerous situations where therapeutic treatments either require or would be assisted by vasculogenesis (the de novo formation of blood vessels). In particular, post-stroke therapies could include treatments that stimulate neovascularization of the affected tissues. The development of such treatments, however, requires thoroughly understanding the developmental properties of endothelial cells and the basic biology of blood vessel formation. While there are many books on angiogenesis, this unique book focuses on exactly this basic biology and explores blood vessel formation in connection with tissue development in a range of animal models. It includes detailed discussions of relevant cell biology, genetics and embryogenesis of blood vessel formation and presents insights into the cross-talk between developing blood vessels and other tissues. With contributions from vascular biologists, cell biologists and developmental biologists, a comprehensive and highly interdisciplinary volume is the outcome.
Download or read book Molecular Mechanisms of Angiogenesis written by Jean-Jacques Feige and published by Springer. This book was released on 2014-05-27 with total page 501 pages. Available in PDF, EPUB and Kindle. Book excerpt: Angiogenesis is a multi-stage process that drives the generation of new blood and lymphatic vessels from pre-existing ones. It is highly active during embryogenesis, largely inactive during adulthood but reactivated during wound healing and under a number of pathological conditions including cancer and ocular diseases. In addition to endothelial cells, which line the walls of the vessels, several other cell types (pericytes, macrophages, progenitor cells...) also contribute to angiogenesis. A number of signaling pathways are activated and very finely tune the delicate morphogenetic events that ultimately lead to the formation of stable blood proof neovessels. This book reviews recent advances in our understanding of the molecular and cellular mechanisms of angiogenesis, with a focus on how to integrate these observations into the context of developmental, post-natal and pathological neovascularization. The book was published under the auspices of the French Angiogenesis Society. Most contributors are prominent members of this Society or international researchers who have actively contributed to the Annual Meetings of the Society.
